Harnessing a germ‑free mouse gut bioreactor for directed evolution of probiotics to combat non-alcoholic fatty liver disease - PubMed
5 hours ago
- #probiotics
- #NAFLD
- #directed evolution
- Directed evolution in probiotics for combating non-alcoholic fatty liver disease (NAFLD) using a germ-free mouse gut bioreactor.
- Host-mediated approach yields a Bifidobacterium animalis subsp. lactis variant with 77% increased bile acid metabolism compared to in vitro methods.
- Identified two critical single-nucleotide variants (SNVs) enhancing bile salt hydrolase expression and bile-acid efflux transporter efficiency.
- Adapted probiotic strain significantly improves bile-acid homeostasis, reduces hepatic steatosis, and lowers inflammatory biomarkers in NAFLD mouse models.
- Framework enables precision engineering of probiotics in vivo, paving the way for personalized microbiome therapeutics.